Abstract
The focus of this chapter is on the future of preclinical abuse liability assessment with an emphasis on new directions for future evaluations. The growth of the rodent comparator compound database for different clinical indications will impact the industry's scientific tools for designing studies to meet the expectations of regulatory agencies. The development of future models for preclinical assessment and approaches for early compound screening to support portfolio decision making are considered as future areas for growth. Problems related to the testing of compounds with poor solubility and nontraditional parameters are discussed. Continued involvement in regulatory discussions and opportunities to impact future guidelines are seen as critical future activities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nonclinical Assessment of Abuse Potential for New Pharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
